Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3′, 5′-cyclic
monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation. Its …

Background Cilostazol is a type III phosphodiesterase inhibitor used to treat the symptoms of
intermittent claudication. Recent studies have shown that cilostazol decreases …

Liver fibrosis is a health challenge requiring alternative therapeutic approaches. Cilostazol
is a selective phosphodiesterase‐3 inhibitor and possesses antioxidant, anti‐inflammatory …

Cilostazol is an antiplatelet that acts by inhibiting phosphodiesterase-3 and that was proven
to be effective in models of ischemia/reperfusion (I/R) injury; however, its possible role in …

The aim of the current study was to determine the hepatoprotective effect and possible
mechanisms of baicalein on CCl4-induced acute liver injury. Male C57BL/6 mice were …

A number of toxic chemicals affect the biliary excretory function of liver. Organochlorines and
halomethanes are known to enhance bile flow. Despite the demonstration that a diversity of …

Background: Cilostazol, a phosphodiesterase 3 inhibitor (PDE3I), is a platelet aggregation
inhibitor and vasodilator that is useful for treating intermittent claudication. Experimental …

Background & Aims Oltipraz (4-methyl-5 (pyrazinyl-2)-1-2-dithiole-3-thione), a promising
cancer preventive agent, has an antioxidative activity and ability to enhance glutathione …

Even though cilostazol was assessed before in several models of atherosclerosis, so far its
full systematic effect as a natural anti-inflammatory and anti-apoptotic mediator in the …

The aim of this work was to compare the effects of colchicine and trimethylcolchicinic acid
(TMCA) on liver damage induced by bile duct ligation (BDL) for 2 months in male Wistar rats …